Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

NCT00784290 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Orantinib (TSU-68)

Sponsor

Taiho Pharmaceutical Co., Ltd.